77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
- Resource Type
- article
- Source
- Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
- Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 2051-1426
95318305